Global testosterone replacement therapy market to rise by $461m by 2029

Its growth is driven by a rising awareness of hypogonadism.

The global testosterone replacement therapy (TRT) market is projected to grow by $461m by 2029 at a compound annual growth rate of 3.3%, according to Technavio.

The sector’s expansion is attributed to the rising awareness initiatives about hypogonadism, a condition characterised by low testosterone levels in men.

Key factors driving the demand for testosterone treatment also include disease severity, inflammation, and ageing.

“TRT is also used to treat conditions like erectile dysfunction, frailty, mobility issues, and neuroscience disorders,” the report said.

“Anti-inflammatory drugs, used to manage metabolic syndrome, have shown potential in restoring testosterone balance,” it added.

Meanwhile, innovations in TRT include the development of drugs, alongside advancements in molecular diagnostics, clinical chemistry, and drug discovery.

The market has also seen significant investment from biotech companies, with TRT tourism emerging as a trend.